BACKGROUND & AIMS: In phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment-experienced cirrhotic and non-cirrhotic patients, but few cirrhotics were included. We report the week 16 safety and efficacy analysis in a cohort of compensated cirrhotics treated in the French Early Access Programme. METHODS: 674 genotype 1 patients, prospectively included, received 48 weeks of triple therapy. The analysis is restricted to 497 patients reaching week 16. RESULTS: A high incidence of serious adverse events (40.0%), and of death and severe complications (severe infection or hepatic decompensation) (6.4%), and a difficult management of anaemia (erythropoietin and transfusion use in 50.7% and 12.1%) were observed. Independent predictors of anaemia < 8 g/dl or blood transfusion were: female gender (OR 2.19, 95% CI 1.11-4.33, p=0.024), no lead-in phase (OR 2.25, 95% CI 1.15-4.39, p=0.018), age ≥ 65 years (OR 3.04, 95% CI 1.54-6.02, p=0.0014), haemoglobin level (≤ 12 g/dl for females, ≤ 13 g/dl for males) (OR 5.30, 95% CI 2.49-11.5, p=0.0001). Death or severe complications were related to platelets count ≤ 100,000/mm(3) (OR 3.11, 95% CI 1.30-7.41, p=0.0105) and albumin <35 g/dl (OR 6.33, 95% CI 2.66-15.07, p=0.0001), with a risk of 44.1% in patients with both. However, the on-treatment virological response was high. CONCLUSIONS: The safety profile was poor and patients with platelet count ≤ 100,000/mm(3) and serum albumin <35 g/L should not be treated with the triple therapy.
BACKGROUND & AIMS: In phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment-experienced cirrhotic and non-cirrhotic patients, but few cirrhotics were included. We report the week 16 safety and efficacy analysis in a cohort of compensated cirrhotics treated in the French Early Access Programme. METHODS: 674 genotype 1 patients, prospectively included, received 48 weeks of triple therapy. The analysis is restricted to 497 patients reaching week 16. RESULTS: A high incidence of serious adverse events (40.0%), and of death and severe complications (severe infection or hepatic decompensation) (6.4%), and a difficult management of anaemia (erythropoietin and transfusion use in 50.7% and 12.1%) were observed. Independent predictors of anaemia < 8 g/dl or blood transfusion were: female gender (OR 2.19, 95% CI 1.11-4.33, p=0.024), no lead-in phase (OR 2.25, 95% CI 1.15-4.39, p=0.018), age ≥ 65 years (OR 3.04, 95% CI 1.54-6.02, p=0.0014), haemoglobin level (≤ 12 g/dl for females, ≤ 13 g/dl for males) (OR 5.30, 95% CI 2.49-11.5, p=0.0001). Death or severe complications were related to platelets count ≤ 100,000/mm(3) (OR 3.11, 95% CI 1.30-7.41, p=0.0105) and albumin <35 g/dl (OR 6.33, 95% CI 2.66-15.07, p=0.0001), with a risk of 44.1% in patients with both. However, the on-treatment virological response was high. CONCLUSIONS: The safety profile was poor and patients with platelet count ≤ 100,000/mm(3) and serum albumin <35 g/L should not be treated with the triple therapy.
Keywords:
AFEF; ALT; ANRS; ATU; Association Française pour l’Etude du Foie; BOC; Boceprevir; CUPIC; Chronic hepatitis C; Cirrhosis; EPO; HBV; HCV; HIV; PI; PegIFN; RBV; SAE; SCAR; SD; SVR; Safety; TVR; Telaprevir; Treatment; agence nationale de recherches sur le SIDA et les hépatites virales; alanine aminotransferase; autorisation temporaire d’utilisation; boceprevir; compassionate use of protease inhibitors in viral C cirrhosis; erythropoietin; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; pegylated interferon; protease inhibitor; ribavirin; serious adverse event; severe cutaneous adverse reaction; standard deviation; sustained virological response; telaprevir
Authors: T Tieghi; R Marocco; V Belvisi; C Del Borgo; S Savinelli; M Lichtner; C M Mastroianni Journal: Infection Date: 2013-10-22 Impact factor: 3.553
Authors: Kian Bichoupan; Valerie Martel-Laferriere; David Sachs; Michel Ng; Emily A Schonfeld; Alexis Pappas; James Crismale; Alicia Stivala; Viktoriya Khaitova; Donald Gardenier; Michael Linderman; Ponni V Perumalswami; Thomas D Schiano; Joseph A Odin; Lawrence Liu; Alan J Moskowitz; Douglas T Dieterich; Andrea D Branch Journal: Hepatology Date: 2014-08-25 Impact factor: 17.425
Authors: V Saxena; M M Manos; H S Yee; L Catalli; E Wayne; R C Murphy; V A Shvachko; M P Pauly; J Chua; A Monto; N A Terrault Journal: Aliment Pharmacol Ther Date: 2014-03-24 Impact factor: 8.171
Authors: Cristiane Valle Tovo; Angelo Alves de Mattos; Paulo Roberto Lerias de Almeida Journal: World J Gastroenterol Date: 2014-03-21 Impact factor: 5.742
Authors: Mattias Mandorfer; Sebastian Steiner; Philipp Schwabl; Berit A Payer; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Thomas Reiberger; Markus Peck-Radosavljevic Journal: Wien Klin Wochenschr Date: 2015-12-10 Impact factor: 1.704